Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma

Shirakawa,Mitsuhiro; Fujiwara,Yoshiyuki; Sugita,Yurika; Moon,Jeong-Ho; Takiguchi,Shuji; Nakajima,Kiyokazu; Miyata,Hiroshi; Yamasaki,Makoto; Mori,Masaki; Doki,Yuichiro

doi:10.3892/or.2011.1607

Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma

Authors:
- Mitsuhiro Shirakawa
- Yoshiyuki Fujiwara
- Yurika Sugita
- Jeong-Ho Moon
- Shuji Takiguchi
- Kiyokazu Nakajima
- Hiroshi Miyata
- Makoto Yamasaki
- Masaki Mori
- Yuichiro Doki
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan, Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita-City, Osaka 565-0871, Japan
Published online on: December 22, 2011 https://doi.org/10.3892/or.2011.1607
Pages: 940-946

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stanniocalcin-1 (STC1) is a secreted glycoprotein hormone and highly expressed in various types of human malignancies. Although evidence points to the role of STC1 in human cancers, the clinical significance of STC1 expression in esophageal cancer has not been well established. Quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry were performed to assess the expression of STC1 in the cancer cell line TE8 and esophageal cancer tissues from 229 esophageal squamous cell carcinomas (ESCC). Surgically-resected tissue sections were immunostained for potential regulators of STC1 expression, hypoxia-inducible factor-1α (HIF-1α) and p53. Marked increase in STC1 mRNA and protein expression was noted in TE8 cells cultured under hypoxic conditions. Overexpression of STC1 mRNA was noted in ESCC tumors compared to normal counterparts. Positive immunohistochemical staining for STC1 protein was observed in 38.9% of patients, and correlated significantly with advanced pT status (p=0.019), poor prognosis [overall survival (p<0.0006) and disease-free survival (p<0.0002) of ESCC patients who had undergone curative surgery]. Positive staining for HIF-1α and p53 proteins in ESCC did not correlate with STC1 expression. The results showed marked induction of STC1 expression under hypoxia in cultured cells and in esophageal cancer cells and that overexpression of STC1 was an independent prognostic factor in patients with esophageal cancer who had undergone curative surgery. STC1 is a potentially useful biomarker for ESCC treatment.

View Figures

View References

1	Sugimachi K, Matsuura H, Kai H, et al: Prognostic factors of esophageal carcinoma: univariate and multivariate analyses. J Surg Oncol. 31:108–112. 1986. View Article : Google Scholar : PubMed/NCBI
2	Natsugoe S, Matsumoto M, Okumura H, et al: Prognostic factors in patients with submucosal esophageal cancer. J Gastrointest Surg. 8:631–635. 2004. View Article : Google Scholar : PubMed/NCBI
3	Ando N, Iizuka T, Ide H, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol. 15:4592–4596. 2003. View Article : Google Scholar : PubMed/NCBI
4	Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092. 2008. View Article : Google Scholar : PubMed/NCBI
5	Fontaine M: Stannius’ corpuscles and ionic (Ca, K, Na) of the interior environment of the eel (Anguilla Anguilla L). C R Hebd Seances Acad Sci. 259:875–878. 1964.
6	Chang ACM, Janosi J, Hulsbeek M, et al: A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol. 112:241–247. 1995. View Article : Google Scholar : PubMed/NCBI
7	Chang AC and Reddel RR: Identification of a second Stanniocalcin cDNA in mouse and human: stanniocalcin 2. Mol Cell Endocrinol. 141:95–99. 1998. View Article : Google Scholar : PubMed/NCBI
8	Fujiwara Y, Sugita Y, Nakamori S, et al: Assessment of Stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers. Int J Oncol. 16:799–804. 2000.PubMed/NCBI
9	Nakagawa T, Martinez SR, Goto Y, et al: Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res. 13:4105–4110. 2007. View Article : Google Scholar : PubMed/NCBI
10	Joensuu K, Heikkilä P and Andersson LC: Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. Cancer Lett. 265:76–83. 2008. View Article : Google Scholar : PubMed/NCBI
11	Law AY, Ching LY, Lai KP, et al: Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. Mol Cell Endocrinol. 314:118–127. 2010. View Article : Google Scholar : PubMed/NCBI
12	Matsuyama J, Doki Y, Yasuda T, et al: The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery. 141:570–580. 2007. View Article : Google Scholar : PubMed/NCBI
13	Yano M, Takachi K, Doki Y, et al: Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Dis Esophagus. 19:158–163. 2006. View Article : Google Scholar : PubMed/NCBI
14	Yamasaki M, Miyata H, Fujiwara Y, et al: p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol. 17:634–642. 2010. View Article : Google Scholar : PubMed/NCBI
15	Makino T, Yamasaki M, Miyata H, et al: p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol. 17:804–811. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wascher RA, Huynh KT, Giuliano AE, et al: Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. Clin Cancer Res. 9:1427–1435. 2003.PubMed/NCBI
17	Paulitschke V, Kunstfeld R, Mohr T, et al: Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J Proteome Res. 8:2501–2510. 2009. View Article : Google Scholar : PubMed/NCBI
18	Chang AC, Jellinek DA and Reddel RR: Mammalian stanniocalcins and cancer. Endocr Relat Cancer. 10:359–373. 2003. View Article : Google Scholar : PubMed/NCBI
19	McCudden CR, James KA, Hasilo C and Wagner GF: Characterization of mammalian stanniocalcin receptors. Mitochondrial targeting of ligand and receptor for regulation of cellular metabolism. J Biol Chem. 277:45249–45258. 2002. View Article : Google Scholar : PubMed/NCBI
20	Maxwell PH, Dachs GU, Gleadle JM, et al: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 94:8104–8109. 1997. View Article : Google Scholar : PubMed/NCBI
21	Wang GL, Jiang BH and Semenza GL: Effect of altered redox states on expression and DNA-binding activity of hypoxia-inducible factor 1. Biochem Biophys Res Commun. 212:550–556. 1995. View Article : Google Scholar : PubMed/NCBI
22	Yeung HY, Lai KP, Chan HY, et al: Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. Endocrinology. 146:4951–4960. 2005. View Article : Google Scholar : PubMed/NCBI
23	Huang LE, Gu J, Schau M and Bunn HF: Regulation of hypoxia-inducible factor 1alpha is mediated by an O₂-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 95:7987–7992. 1998. View Article : Google Scholar : PubMed/NCBI
24	Lai KP, Law AY, Yeung HY, et al: Induction of stanniocalcin-1 expression in apoptotic human nasopharyngeal cancer cells by p53. Biochem Biophys Res Commun. 356:968–975. 2007. View Article : Google Scholar : PubMed/NCBI
25	Brown JM and Wilson WR: Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004. View Article : Google Scholar
26	Vaupel P, Thews O and Hoeckel M: Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. 18:243–259. 2001. View Article : Google Scholar : PubMed/NCBI
27	Cohen P and Frame S: The renaissance of GSK3 (Review). Nat Rev Mol Cell Biol. 2:769–776. 2001. View Article : Google Scholar : PubMed/NCBI
28	Thompson JE and Thompson CB: Putting the rap on Akt. J Clin Oncol. 22:4217–4226. 2004. View Article : Google Scholar : PubMed/NCBI
29	Comerford KM, Wallace TJ, Karhausen J, et al: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62:3387–3394. 2002.PubMed/NCBI
30	Sullivan R, Paré GC, Frederickson LJ, et al: Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 7:1961–1973. 2008. View Article : Google Scholar : PubMed/NCBI
31	Kita Y, Mimori K, Iwatsuki M, et al: STC2: A predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma. Ann Surg Oncol. 18:261–272. 2011. View Article : Google Scholar : PubMed/NCBI
32	Law AY and Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res. 316:466–476. 2010. View Article : Google Scholar : PubMed/NCBI